News & Updates

People living with HIV (PWH) may soon benefit from a once-weekly treatment regimen instead of the standard daily antiretroviral therapy to manage their condition. Two recent phase III trials, ISLEND-1 and -2, have shown the efficacy of islatravir/lenacapavir (ISL/LEN) vs bictegravir/emtricitabine/tenofovir/alafenamide (B/F/TAF) or standard of care (SOC).

In a prespecified secondary analysis of the phase III FLOW trial, semaglutide reduces the risk of serious infections and COVID-19 events in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Therapeutic-dose anticoagulation has contributed to a decrease in the likelihood of organ support or death among noncritically ill hospitalized patients with COVID-19. Such experience shows how quick and rigorous approaches, when aligned, can promptly translate evidence into practice, suggests a study.